Qiagen N.V. (QGEN) Raised to “Buy” at Zacks Investment Research

Qiagen N.V. (NASDAQ:QGEN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday. The firm presently has a $39.00 price objective on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 11.30% from the company’s current price.

According to Zacks, “QIAGEN’s commitment to return more to its shareholders through increased share repurchases reflects solid cash position. We are also upbeat about QIAGEN’s partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio. Moreover, the company’s strategic focus to drive growth through Sample to Insight offerings buoys optimism. QIAGEN is forming collaborations in the personalized homecare space also. Moreover, QIAsymphony continued to grow towards the target of 2,000 cumulative placements by 2017 end. On the flip side, over the last three months, QIAGEN has been trading below the broader industry. Moreover, adverse currency translation continues to be a drag on overall sales. Furthermore, declining HPV sales in the United States continues to be a drag. Competitive landscape and strong reliance on collaborations also continue to be concerns.”

Several other research analysts have also weighed in on QGEN. Commerzbank Ag reiterated a “buy” rating on shares of Qiagen N.V. in a research note on Friday, June 23rd. BidaskClub lowered shares of Qiagen N.V. from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Morgan Stanley reiterated an “overweight” rating and issued a $37.00 price objective (up previously from $36.00) on shares of Qiagen N.V. in a research note on Monday, July 10th. Wells Fargo & Company reiterated a “market perform” rating and issued a $31.00 price objective (up previously from $28.00) on shares of Qiagen N.V. in a research note on Thursday, July 13th. Finally, Barclays PLC reiterated an “overweight” rating and issued a $37.00 price objective (up previously from $33.00) on shares of Qiagen N.V. in a research note on Monday, July 17th. Eight research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $33.28.

Shares of Qiagen N.V. (NASDAQ QGEN) traded down 1.51% during mid-day trading on Tuesday, hitting $34.51. 1,733,642 shares of the stock traded hands. The company has a market cap of $7.88 billion, a price-to-earnings ratio of 105.54 and a beta of 1.14. Qiagen N.V. has a 52 week low of $24.89 and a 52 week high of $35.47. The stock has a 50-day moving average of $32.14 and a 200-day moving average of $32.07.

Qiagen N.V. (NASDAQ:QGEN) last released its quarterly earnings data on Thursday, July 27th. The company reported $0.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.28 by $0.02. The firm had revenue of $349.00 million for the quarter, compared to analyst estimates of $353.09 million. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.24 EPS. Analysts anticipate that Qiagen N.V. will post $1.21 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Qiagen N.V. (QGEN) Raised to “Buy” at Zacks Investment Research” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://ledgergazette.com/2017/10/10/qiagen-n-v-qgen-raised-to-buy-at-zacks-investment-research.html.

Several institutional investors and hedge funds have recently made changes to their positions in QGEN. BlackRock Inc. increased its stake in shares of Qiagen N.V. by 8,793.4% during the 1st quarter. BlackRock Inc. now owns 7,839,636 shares of the company’s stock worth $227,114,000 after purchasing an additional 7,751,485 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Qiagen N.V. by 2,651.3% during the 1st quarter. Legal & General Group Plc now owns 1,896,813 shares of the company’s stock worth $16,690,000 after buying an additional 1,827,871 shares during the period. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Qiagen N.V. during the 1st quarter worth $46,480,000. Renaissance Technologies LLC boosted its holdings in shares of Qiagen N.V. by 182.9% during the 1st quarter. Renaissance Technologies LLC now owns 1,514,898 shares of the company’s stock worth $43,890,000 after buying an additional 979,498 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Qiagen N.V. during the 2nd quarter worth $26,408,000. Institutional investors own 63.01% of the company’s stock.

Qiagen N.V. Company Profile

QIAGEN N.V.

According to Zacks, “QIAGEN’s commitment to return more to its shareholders through increased share repurchases reflects solid cash position. We are also upbeat about QIAGEN’s partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio. Moreover, the company’s strategic focus to drive growth through Sample to Insight offerings buoys optimism. QIAGEN is forming collaborations in the personalized homecare space also. Moreover, QIAsymphony continued to grow towards the target of 2,000 cumulative placements by 2017 end. On the flip side, over the last three months, QIAGEN has been trading below the broader industry. Moreover, adverse currency translation continues to be a drag on overall sales. Furthermore, declining HPV sales in the United States continues to be a drag. Competitive landscape and strong reliance on collaborations also continue to be concerns.”

Several other research analysts have also weighed in on QGEN. Commerzbank Ag reiterated a “buy” rating on shares of Qiagen N.V. in a research note on Friday, June 23rd. BidaskClub lowered shares of Qiagen N.V. from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Morgan Stanley reiterated an “overweight” rating and issued a $37.00 price objective (up previously from $36.00) on shares of Qiagen N.V. in a research note on Monday, July 10th. Wells Fargo & Company reiterated a “market perform” rating and issued a $31.00 price objective (up previously from $28.00) on shares of Qiagen N.V. in a research note on Thursday, July 13th. Finally, Barclays PLC reiterated an “overweight” rating and issued a $37.00 price objective (up previously from $33.00) on shares of Qiagen N.V. in a research note on Monday, July 17th. Eight research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $33.28.

Shares of Qiagen N.V. (NASDAQ QGEN) traded down 1.51% during mid-day trading on Tuesday, hitting $34.51. 1,733,642 shares of the stock traded hands. The company has a market cap of $7.88 billion, a price-to-earnings ratio of 105.54 and a beta of 1.14. Qiagen N.V. has a 52 week low of $24.89 and a 52 week high of $35.47. The stock has a 50-day moving average of $32.14 and a 200-day moving average of $32.07.

Qiagen N.V. (NASDAQ:QGEN) last released its quarterly earnings data on Thursday, July 27th. The company reported $0.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.28 by $0.02. The firm had revenue of $349.00 million for the quarter, compared to analyst estimates of $353.09 million. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.24 EPS. Analysts anticipate that Qiagen N.V. will post $1.21 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Qiagen N.V. (QGEN) Raised to “Buy” at Zacks Investment Research” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://ledgergazette.com/2017/10/10/qiagen-n-v-qgen-raised-to-buy-at-zacks-investment-research.html.

Several institutional investors and hedge funds have recently made changes to their positions in QGEN. BlackRock Inc. increased its stake in shares of Qiagen N.V. by 8,793.4% during the 1st quarter. BlackRock Inc. now owns 7,839,636 shares of the company’s stock worth $227,114,000 after purchasing an additional 7,751,485 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Qiagen N.V. by 2,651.3% during the 1st quarter. Legal & General Group Plc now owns 1,896,813 shares of the company’s stock worth $16,690,000 after buying an additional 1,827,871 shares during the period. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Qiagen N.V. during the 1st quarter worth $46,480,000. Renaissance Technologies LLC boosted its holdings in shares of Qiagen N.V. by 182.9% during the 1st quarter. Renaissance Technologies LLC now owns 1,514,898 shares of the company’s stock worth $43,890,000 after buying an additional 979,498 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Qiagen N.V. during the 2nd quarter worth $26,408,000. Institutional investors own 63.01% of the company’s stock.

Qiagen N.V. Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply